Engraftment syndrome (ES), which develops in 7-59% of individuals undergoing hematopoietic SCT (HSCT), is a significant cause of early morbidity and nonrelapse-related mortality. 1 This syndrome, characterized by noninfectious fever, skin rash, unexplained weight gain and noncardiogenic pulmonary edema, generally occurs immediately before or at the time of neutrophil engraftment. 1 The pathogenesis of ES remains to be fully elucidated, although increased production of proinflammatory cytokines, which can be stimulated by exogenous G-CSF during neutrophil recovery in conjunction with toxicity of the conditioning regimen, is thought to have a role. 1 Corticosteroids are used to alleviate the clinical symptoms of ES, but heighten the risk of infection in neutropenic patients.
Recombinant human soluble thrombomodulin (rTM) is composed of the active, extracellular domain of thrombomodulin, 2 and inactivates coagulation by binding to thrombin. In addition, the thrombin-rTM complex activates protein C to produce activated protein C, which in the presence of protein S inactivates factors VIIIa and Va, thereby inhibiting further thrombin formation. 3 A recent phase III trial comparing the efficacy and safety of rTM to those of low-dose heparin showed that rTM significantly improved disseminated intravascular coagulation (DIC) associated with hematological malignancies or infections. 3 Use of rTM for the treatment of DIC has recently been approved in Japan.
We describe a patient with ES with coagulation abnormalities following HSCT who was successfully treated by rTM.
In December 2009, a 68-year-old man with myelodysplastic syndrome transforming to overt leukemia underwent allo-HSCT from a 2-locus HLA-mismatched unrelated donor. He had received three courses of induction chemotherapy with either idarubicin (12 mg/m 2 / day Â 3 days), mitoxantrone (8 mg/m 2 /day Â 3 days) or daunorubicin (50 mg/m 2 /day Â 5 days) in combination with cytarabine (100 mg/m 2 /day Â 7 days), which failed to effect remission; 40% leukemic blasts remained in the BM. Conditioning for transplantation consisted of TBI at 4 Gy with fludarabine and BU. GVHD prophylaxis included tacrolimus and mycophenolate mofetil. On day 8 post transplant, he experienced fever that did not respond to tazobactam-piperacillin. G-CSF (450 mg) was initiated to stimulate neutrophil engraftment on day 13. At that time his body weight began to increase and reached a 6% weight gain by day 18 post transplant, when his neutrophil counts started to increase. Chest X-ray and chest computed tomography identified noncardiogenic pulmonary edema ( Figure 1a) and oxygen was required. The diagnosis of ES was established according to the diagnostic criteria of ES proposed by Spitzer, 1 although neither skin rash nor renal insufficiency were apparent. Simultaneously, he was in a state of non-overt DIC; coagulation tests on days 12 and 14 revealed abnormalities with a prolonged prothrombin time of 13.5 s and elevated levels of fibrinogen degradation products of 8.2 mg/mL, respectively, although plasma levels of fibrinogen and activated partial thromboplastin time remained within normal ranges. Plasma levels of antithrombin III dropped to 56.9%, and we therefore repeatedly administered antithrombin III concentrate, which did not improve the coagulation abnormality (Figure 1b) . In addition, plasma levels of soluble fibrin monomer complex (SFMC) continued to increase and reached 14.1 mg/mL on day 18, prompting us to initiate rTM (380 U/kg). Surprisingly, his body weight began to decrease on day 23 in association with improvement in pulmonary edema (Figure not shown) and normalized within 2 weeks. No diuretics or corticosteroid were administered. Coagulation tests also started to normalize. Plasma levels of SFMC transiently jumped to 24.5 mg/mL on day 21; however, they promptly fell to within the normal range on the following day. The WBC count recovered to 2100/mL without discontinuation of G-CSF (Figure 1b) . This is the first report of rTM alleviating weight gain and pulmonary edema associated with ES after HSCT without administration of corticosteroids. Coagulation tests indicated a state of non-overt DIC in this patient when ES developed. Overproduction of cytokines stimulated by G-CSF together with cytotoxic agents in the conditioning regimen and TBI may have caused endothelial cell damage, resulting in development of ES and a hypercoagulable state. rTM was able to counteract capillary leakage through activated protein C-dependent mechanisms; activated protein C is known to cleave and activate proteaseactivated receptor-1, which binds to endothelial protein C receptor and enhances vascular barriers in murine septic models. 4 In addition, a phase III clinical trial has shown that rTM increases levels of antithrombin III and decreases levels of plasminogen activator inhibitor 1 in patients with DIC, 3 suggesting a possible role of rTM in protecting endothelial cells from injury.
G-CSF is known to stimulate the production of vessel endothelial growth factor (VEGF), which increases endothelial permeability and could be related to the pathogenesis of capillary leak syndrome, including ES. Surprisingly, plasma levels of VEGF were not elevated in this patient (data not shown). Another candidate molecule that could cause capillary leakage in ES is bradykinin.
Thrombomodulin forms a complex with thrombin and activates thrombin-activated fibrinolysis inhibitor (TAFI), a latent plasma procarboxypeptidase, on the endothelial Letter to the Editor cell surface. Activated TAFI (TAFIa) inhibits bradykinin. 6 In addition, in vitro studies have shown that TAFIa abrogated C5a-induced activation of neutrophils. 6 Further studies are clearly required to verify the involvement of bradykinin in the pathogenesis of ES, as well as the action of TAFIa on G-CSF-stimulated neutrophils.
Another possible mechanism by which rTM attenuates ES is related to its anti-inflammatory activity. The N-terminal domain of TM binds to and inactivates highmobility group box 1 protein, a proinflammatory cytokine that stimulates the production of inflammatory cytokines such as IL-6 and TNF-a through toll-like receptor 4 and receptors for advanced glycation end products. 7 Aberrant production of proinflammatory cytokines is considered to induce endothelial cell damage and may be involved in the pathogenesis of ES. As a result, rTM may alleviate ES through inactivation of these proinflammatory cytokines.
Given the present findings, administration of rTM may offer an effective method for treating coagulation abnormalities, as well as capillary leak syndrome caused by HSCT, such as ES and SOS.
